Evotec acquires Bionamics for undisclosed sum


Expands discovery pipeline with portfolio of MS and CNS projects

Evotec has acquired Germany-based Bionamics, an asset management company that turns academic innovations into attractive assets for the biotech and pharma industry.

The deal includes the acquisition of all shares of the Hamburg-based company against cash and future milestone payments.

Further financial details of the transaction have not been disclosed.

Bionamics, which employs three people, has set up and manages NEU² (www.neu-quadrat.de) a consortium established to generate new treatment options in neurodegenerative diseases and supported by public funds of up to €40m.

Werner Lanthaler, Chief Executive of Evotec, said the acquisition would enable Evotec to accelerate its EVT Innovate strategy and 'enlarge our reach towards outstanding innovations'.

Timm Jessen, Managing Director of Bionamics, added: 'The combination of our management skills with Evotec’s strong operational capabilities offers a unique constellation for researchers and entrepreneurs around the globe to accelerate their innovation together with us.'

Sign up for your free email newsletter

Before founding Bionamics in 2006, Jessen was Chief Scientific Officer at Evotec from 1997 to 2004.